Eris Lifesciences Limited has successfully drawn down a working capital term loan amounting to ₹64,40,00,000/- (Rupees Sixty Four Crores Forty Lakhs Only) from Axis Bank Limited. This facility is intended to manage other short-term liabilities. The company has confirmed that its aggregate debt level will remain unchanged as a result of this transaction.
Working Capital Financing Secured
Eris Lifesciences Limited has announced the drawdown of a new working capital term loan facility. The total amount borrowed from Axis Bank Limited is ₹64,40,00,000/-, which is equivalent to Rupees Sixty Four Crores Forty Lakhs Only. This financing is earmarked for addressing existing short-term liabilities within the company’s operations.
Debt Level Unchanged
Despite the new borrowing, Eris Lifesciences has clarified that the overall aggregate debt level of the company will not change. This indicates that the new loan may have been used to refinance existing debt or that other financial adjustments have been made concurrently to maintain the debt equilibrium. The sanction letter for this loan agreement was executed on 05th August 2026.
Loan Details and Security
The loan obtained from Axis Bank Limited is categorized as a Working Capital Term Loan. The lender is Axis Bank Limited, and the borrower is Eris Lifesciences Limited. The total amount granted is ₹64,40,00,000/-. The company has provided a second charge on its assets, both primary and collateral, which were already pledged for its existing working capital credit facilities, as security for this new loan.
Source: BSE
